MedTrace Logo

Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia

NCT02096328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-11-28

No results posted yet for this study

Summary

To investigate the pharmacokinetic characteristics of POL7080 co-administered with SoC during 10 to 14 days of treatment in VAP patients due to suspected or documented Pseudomonas aeruginosa infection

Conditions

  • Ventilator Associated Pneumonia
  • Lower Respiratory Infection

Interventions

DRUG

POL7080

Intravenous infusion

Sponsors & Collaborators

  • Polyphor Ltd.

    lead INDUSTRY

Principal Investigators

  • Antoni Torres, MD PhD · Hospital Clinic, Barcelona, SPAIN

  • Evangelos Giamarellos-Bourboulis, MD PhD · ATTIKON University Hospital, Athens, GREECE

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • Greece
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02096328 on ClinicalTrials.gov